NCT00044889View on ClinicalTrials.gov

Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

March 31, 2003

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG

clofarabine (IV formulation)

Trial Locations (12)

Unknown

Los Angeles

Washington D.C.

Jacksonville

Chicago

St Louis

Omaha

Buffalo

Durham

Memphis

Houston

Norfolk

Seattle

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00044889 - Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter